文献速递免疫规划

2012-2016年美国参保男性四价人乳头瘤病毒疫苗的接种启动与3剂系列完成情况

Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012-2016.
PubMed 文献 · Vaccine · 2021-11-20

研究利用美国健康保险索赔数据库,纳入2012至2016年间启动四价人乳头瘤病毒(4vHPV)疫苗接种的9至26岁男性100786人,分析接种模式与完成3剂系列的相关因素。结果显示仅50.2%和25.6%的男性分别接种了第二剂和第三剂,47%的男性在3年内每年接种1剂,而仅12%在推荐的6个月内完成3剂系列。18至21岁、居住于西部各州或农村地区的男性完成3剂系列的可能性更低。

要点

  • 100786名启动4vHPV的男性中,仅50.2%接种第二剂、25.6%接种第三剂。
  • 47%的男性在3年内每年接种1剂,仅12%在推荐6个月内完成3剂系列。
  • 18至21岁及居住西部或农村地区的男性完成3剂系列的可能性更低。

核心结论

  • 实际观察到的4vHPV接种模式,尤其是低接种率和低系列完成率,提示需要更好的策略来改善男性4vHPV疫苗的使用。

研究设计与样本

  • 研究使用美国健康保险索赔数据库,纳入2012至2016年间启动4vHPV的9至26岁男性,估计首剂至后续剂次的时间,并用 logistic 回归识别与方案完成相关的因素。

主要发现

  • 在100786名启动4vHPV的男性中,50573人(50.2%)接种了第二剂,25763人(25.6%)接种了第三剂。
  • 47%的男性在3年内接种3剂(每年1剂),而12%的男性在推荐的6个月时间内完成3剂系列。
  • 与其他时间相比,夏季月份接种4vHPV的可能性是其他时间的2.2倍(范围1.5至2.9)。
  • 18至21岁个体以及居住于西部各州或农村地区的个体完成3剂方案的可能性更低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The quadrivalent human papillomavirus vaccine (4vHPV, GARDASIL®), was approved in the US in 2009 for use in males aged 9 to 26 for the prevention of HPV-related genital warts, and in 2010 for the prevention of certain HPV-related anogenital diseases. A regimen was approved in 2016 for those who initiate the vaccine series between the ages of 9 to 14 years. We describe patterns of 4vHPV administration among US males before this modification. METHODS: The study used a US health insurance claims database, and included males, age 9 to 26 years, who initiated 4vHPV between 2012 and 2016. Time from first dose to subsequent doses was estimated. Logistic regression identified factors associated with regimen completion. RESULTS: Among 100,786 males who initiated 4vHPV (corresponding to ∼ 13% of male birth cohorts), 50,573 (50.2%) and 25,763 (25.6%) received a second and third dose, respectively. Annual administration was common, with 47% of males receiving 3 doses over 3 years (1 dose per year) as compared to 12% receiving the 3-dose series in the recommended 6-month timeframe. Receipt of 4vHPV was 2.2 (range 1.5 to 2.9) times as likely to occur in summer months compared to other times of the year. Individuals aged 18 to 21 years and those living in Western states or rural regions were less likely to complete the 3-dose regimen. CONCLUSIONS: The real-world patterns of 4vHPV vaccination observed, particularly the low uptake and regimen completion, suggest that better strategies are needed for males to improve 4vHPV vaccine use in males.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Amend KL, Turnbull B, Zhou L, et al. Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males 2012-2016. Vaccine. 2021. PMID: 34794821. doi:10.1016/j.vaccine.2021.10.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。